Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: Evaluation of eryptotic pathway

Toxicology

Volumn 294, Issue 1, 2012, Pages 54-60

  Ganesan, Shobana ^a,b,c   Chaurasiya, Narayan D ^a   Sahu, Rajnish ^a   Walker, Larry A ^a,b   Tekwani, Babu L ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Eryptosis; Erythrocytes; Glucose 6 phosphate dehydrogenase deficiency; Hemolytic toxicity; Methemoglobin; Oxidative stress; Primaquine

Indexed keywords

GLUCOSE 6 PHOSPHATE DEHYDROGENASE; LIPOCORTIN 5; METHEMOGLOBIN; MOLECULAR MARKER; PRIMAQUINE;

ARTICLE; BINDING ASSAY; CELL ASSAY; CIRCULATION; CLEARANCE; CONTROLLED STUDY; ERYTHROCYTE METABOLISM; FLOW CYTOMETRY; HEMOLYTIC TOXICITY; HUMAN; LIVER MICROSOME METABOLISM; NORMAL HUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; TOXICITY;

ANNEXINS; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMANS; METHEMOGLOBIN; OXIDATIVE STRESS; PRIMAQUINE; REACTIVE OXYGEN SPECIES;

EID: 84857798694     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2012.01.015     Document Type: Article

References (37)

1. Beutler E., Dern R.J., Alving A.S. The hemolytic effect of primaquine. III. A study of primaquine sensitive erythrocytes. J. Lab. Clin. Med. 1954, 44:177-184.
2. Beutler E., Westwood B., Prchal J.T., Vaca G., Bartsocas C.S., Baronciani L. New glucose-6-phosphate dehydrogenase mutations from various ethnic groups. Blood 1992, 80:255-256.
3. Bloom K.E., Brewer G.J., Magon A.M., Wetterstroem N. Microsomal incubation test of potentially hemolytic drugs for glucose-6-phosphate dehydrogenase deficiency. Clin. Pharmacol. Ther. 1983, 33:403-409.
4. Boas F.E., Forman L., Beutler E. Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:3077-3081.
5. Baird J.K., Davidson D.E., Decker-Jackson J.E. Oxidative activity of hydroxylated primaquine analogs. Biochem. Pharmacol. 1986, 35:1091-1098.
6. Baird J.K., McCormic G.J., Canfield C.J. Effects of nine synthetic putative metabolites of primaquine on activity of the hexose monophosphate shunt in intach human and red blood cells in vitro. Biochem. Pharmacol. 1986, 35:1099-1106.
7. Bousema T., Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin. Microbiol. Rev. 2011, 24:377-410.
8. Bowman Z.S., Morrow J.D., Jollow D.J., McMillan D.C. Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine. J. Pharmacol. Exp. Ther. 2004, 309:79-85.
9. Bowman Z.S., Morrow J.D., Jollow D.J., McMillan D.C. Primaquine-induced hemolytic anemia: role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5-hydroxyprimaquine. J. Pharmacol. Exp. Ther. 2005, 314:838-845.
10. Bowman Z.S., Jollow D.J., McMillan D.C. Primaquine-induced hemolytic anemia: role of splenic macrophages in the fate of 5-hydroxyprimaquine-treated rat erythrocytes. J. Pharmacol. Exp. Ther. 2005, 315:980-986.
11. Burgoine K.L., Bancone G., Nosten F. The reality of using primaquine. Malar. J. 2010, 9:376.
12. Clyde D.F. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull. World Health Organ. 1981, 59:391-395.
13. Duranton C., Huber S.M., Lang F. Oxidation induces a Cl(-)-dependent cation conductance in human red blood cells. J. Physiol. 2002, 539:847-855.
14. Fernando D., Rodrigo C., Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar. J. 2011, 10:351.
15. Flanagan C.L., Schrier S.L., Carson P.E., Alving A.S. The hemolytic effect of primaquine. VIII. The effect of drug administration on parameters of primaquine sensitivity. J. Lab. Clin. Med. 1958, 51:600-608.
16. Fletcher K.A., Barton P.E., Kelly J.A. Studies n the mechanism of oxidation in the erythrocytes by metabolites of primaquine. Biochem. Pharmacol. 1988, 37:2683-2690.
17. Föller M., Bobbala D., Koka S., Huber S.M., Gulbins E., Lang F. Suicide for survival-death of infected erythrocytes as a host mechanism to survive malaria. Cell. Physiol. Biochem. 2009, 24:133-140.
18. 450-dependent toxic effects of primaquine on human erythrocytes. Toxicol. Appl. Pharmacol. 2009, 15:14-22.
19. 450-dependent toxicity of dapsone in human erythrocytes. J. Appl. Toxicol. 2010, 30:271-275.
20. Idowu O.R., Peggins J.O., Brewer T.G. Side-chain hydroxylation in the metabolism of 8-aminoquinoline antiparasitic agents. Drug. Metab. Dispos. 1995, 23:18-27.
21. Jansson S.E., Hekali R., Gripenberg J., Härkönen M., Vuopio P. Membrane characteristics and metabolic properties of glucose-6-phosphate dehydrogenase deficient red cells. Br. J. Haematol. 1980, 46:79-87.
22. 2 formation, or glutathione turnover. Biochem. Pharmacol. 1982, 31:2409-2414.
23. Koliwad S.K., Elliott S.J., Kunze D.L. Oxidized glutathione mediates cation channel activation in calf vascular endothelial cells during oxidant stress. J. Physiol. 1996, 495:37-49.
24. Lang F., Lang K.S., Lang P.A., Huber S.M., Wieder T. Mechanisms and significance of eryptosis. Antioxid. Redox. Signal. 2006, 8:1183-1192.
25. Lang F., Gulbins E., Lerche H., Huber S.M., Kempe D.S., Foller M. Eryptosis, a window to systemic disease. Cell. Physiol. Biochem. 2008, 22:373-380.
26. + channels in human erythrocyte apoptosis. Am. J. Physiol. Cell. Physiol. 2003, 285:1553-1560.
27. Link C.M., Theoharides A.D., Anders J.C., Chung H., Canfield C.J. Structure-activity relationships of putative primaquine metabolites causing methemoglobin formation in canine hemolysates. Toxicol. Appl. Pharmacol. 1985, 81:192-202.
28. Ramos W.M., Sardinha J.F., Costa M.R., Santana M.S., Alecrim M.G., Lacerda M.V. Clinical aspects of hemolysis in patients with P. vivax malaria treated with primaquine, in the Brazilian Amazon. Braz. J. Infect. Dis. 2010, 14:410-412.
29. Sivilotti M.L. Oxidant stress and haemolysis of the human erythrocyte. Toxicol. Rev. 2004, 23:169-188.
30. Summerfield M., Tudhope G.R. Studies with primaquine in vitro: superoxide radical formation and oxidation of haemoglobin. Br. J. Clin. Pharmacol. 1978, 6:319-323.
31. Taylor W.R., White N.J. Antimalarial drug toxicity: a review. Drug. Saf. 2004, 27:25-61.
32. Tekwani B.L., Walker L.A. 8-Aminoquinolines: future role as antiprotozoals. Curr. Opin. Infect. Dis. 2006, 19:623-631.
33. Vale N., Moreira R., Gomes P. Primaquine revisited six decades after its discovery. Eur. J. Med. Chem. 2009, 44:937-953.
34. Vickers A.E.M., Sinclair J.R., Fisher R.L., Morris S.R., Way W. Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol. Appl. Pharmacol. 2010, 244:354-365.
35. Vásquez-Vivar J., Augusto O. Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. J. Biol. Chem. 1992, 267:6848-6854.
36. Wells T.N., Burrow J.N., Baird J.K. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010, 26:145-151.
37. Youngster I., Arcavi L., Schechmaster R., Akayzen Y., Popliski H., Shimonov J., Beig S., Berkovitch M. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf. 2010, 33:713-726.